908 Devices Inc., an expert in purpose-built handheld and desktop devices for chemical and biochemical analysis, and Cellares, an Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and commercial-scale cell therapy manufacturing, have entered a development collaboration to integrate in-line monitoring of key cell culture parameters into Cellares’ Cell Shuttle system, a fully integrated, scalable, cell therapy manufacturing platform.
 
The collaboration between the two companies aims to further advance the efficiency, safety, and cost-effectiveness of large-scale cell therapy manufacturing.

Enhancing the Cell Shuttle System with MAVERICK

908 Devices is integrating its optical in-line analyzer, MAVERICK, the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling or development required. MAVERICK’s purpose-built de novo models automatically process Raman spectra from a wide variety of culture media types and cell lines, delivering actionable process parameters or direct process control actions. The company is adapting its MAVERICK device to be integrated into the Cell Shuttle system.
 
“In-line analysis provides real-time monitoring of the cell culture process, allowing for immediate corrective action. It also maintains sample integrity, reduces contamination risk, and improves product quality,” said Christopher D. Brown, PhD, Chief Product Officer and Co-founder, 908 Devices. “We’re very proud to partner with Cellares to accelerate access to life-saving cell therapies.”
 
“We are pleased to announce our collaboration with 908 Devices,” remarked Daniele Malleo, PhD, Cellares VP of Research and Development. “The integration of the 908’s MAVERICK Raman Spectrometer into Cellares’ fully automated, closed end-to-end cell therapy manufacturing platform will enable real-time process control of key cellular parameters, enhancing the efficiency and safety of cell therapy production while significantly reducing costs. This collaboration is a testament to our vision of making advanced cell therapies more accessible and affordable, ultimately accelerating the delivery of these critical treatments to patients who need them.”

Related News

Earlier this year, Cellares announced a $255 million series C fundraise to launch its new 118,000-sq. ft. manufacturing site in Bridgewater, New Jersey.